Sarcoglycanopathies: state of the art and therapeutic perspectives

Sarcoglycanopathies are the third most common cause of autosomal recessive limb girdle muscular dystrophies (LGMD). They are the result of a deficiency in one of the sarcoglycans a, b, g, or d. The usual clinical presentation is that of a symmetrical involvement of the muscles of the pelvic and scap...

Full description

Saved in:
Bibliographic Details
Published inM.S. Médecine sciences Vol. 36 Hors série n° 2; pp. 22 - 27
Main Authors Fernández-Eulate, Gorka, Leturcq, France, Laforêt, Pascal, Richard, Isabelle, Stojkovic, Tanya
Format Journal Article
LanguageFrench
Published France EDP Sciences 01.12.2020
Subjects
Online AccessGet full text
ISSN1958-5381
0767-0974
1958-5381
DOI10.1051/medsci/2020243

Cover

More Information
Summary:Sarcoglycanopathies are the third most common cause of autosomal recessive limb girdle muscular dystrophies (LGMD). They are the result of a deficiency in one of the sarcoglycans a, b, g, or d. The usual clinical presentation is that of a symmetrical involvement of the muscles of the pelvic and scapular girdles as well as of the trunk, associated with more or less severe cardio-respiratory impairment and a marked increase of serum CK levels. The first symptoms appear during the first decade, the loss of ambulation occurring often during the second decade. Lesions observed on the muscle biopsy are dystrophic. This is associated with a decrease or an absence of immunostaining of the sarcoglycan corresponding to the mutated gene and, to a lesser degree, of the other three sarcoglycans. Many mutations have been reported in the four incriminated genes and some of them are prevalent in certain populations. To date, there is no curative treatment, which does not prevent the development of many clinical trials, especially in gene therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1958-5381
0767-0974
1958-5381
DOI:10.1051/medsci/2020243